SbbPerson

I just answered this question.

My Score PASS  

I just answered this question.

My Score PASS  

I just answered this question.

My Score FAIL  

I just answered this question.

My Score PASS  

I just answered this question.

My Score PASS  

Thanks, sbbguy. At first I thought maybe the mom is A2 type, too. But she is A1 type with pos DAT due to IgG. I feel so confused.

The mom is probably a subgroup of Group A, perhaps she is A2 type. If so, she probably has Anti-A1. Subgroup A cells will react with Anti-A reagents. 
From first read of your post, I was thinking maybe the Anti-A1 was passed through the breast milk. But if I am not mistaken, Anti-A1 is an IgM antibody, and those don't usually get passed through breastmilk. Let me dig further into this and see what I can find. Good luck.

We had a melanoma patient on Nivolumab = Opdivo who apparently has hemolytic anemia but his IgG was only microscopically positive and his complement was negative.  Hgb 5.5. Retic % slightly elevated, absolute retic normal, immature fraction retic very high. Bili and LDH normal. Hpt <14 and responded to steroids.  They blamed this drug so I hunted up this article.  This was new to me so I wanted to share it.
Clinical Trial Am J Hematol  2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
Rebecca Karp Leaf 1, Christopher Ferreri 2, Deepa Rangachari 3, James Mier 3, Wesley Witteles 4, George Ansstas 5, Theodora Anagnostou 6, Leyre Zubiri 1, Zofia Piotrowska 1, Thein H Oo 7, David Iberri 8, Mark Yarchoan 9, April K S Salama 10, Douglas B Johnson 11, Andrew D Leavitt 12, Osama E Rahma 13, Kerry L Reynolds 1, David E Leaf 14
PMID: 30790338 DOI: 10.1002/ajh.25448
Free article
Abstract
Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is a rare, but often severe, complication of ICPis. We identified 14 patients from nine institutions across the United States who developed ICPi-AIHA. The median interval from ICPi initiation to development of AIHA was 55 days (interquartile range [IQR], 22-110 days). Results from the direct antiglobulin test (DAT) were available for 13 of 14 patients: 8 patients (62%) had a positive DAT and 5 (38%) had a negative DAT. The median pretreatment and nadir hemoglobin concentrations were 11.8 g/dL (IQR, 10.2-12.9 g/dL) and 6.3 g/dL (IQR, 6.1-8.0 g/dL), respectively. Four patients (29%) had a preexisting lymphoproliferative disorder, and two (14%) had a positive DAT prior to initiation of ICPi therapy. All patients were treated with glucocorticoids, with three requiring additional immunosuppressive therapy. Complete and partial recoveries of hemoglobin were achieved in 12 (86%) and 2 (14%) patients, respectively. Seven patients (50%) were re-challenged with ICPis, and one (14%) developed recurrent AIHA. Clinical and laboratory features of ICPi-AIHA were similar in DAT positive and negative patients. ICPi-AIHA shares many clinical features with primary AIHA; however, a unique aspect of ICPi-AIHA is a high incidence of DAT negativity. Glucocorticoids are an effective first-line treatment in the majority of patients with ICPi-AIHA, and most patients who are re-challenged with an ICPi do not appear to develop recurrence of AIHA.
 
 
 

What are RTTIs?
This information in this question / answer was generously provided by AABB. Any errors are those of the site admin, not AABB.
Mention of specific products or equipment in this AABB publication does not represent an endorsement of such products by the AABB nor does it necessarily indicate a preference for those products over similar competitive products.
Efforts are made to have publications of the AABB consistent in regard to acceptable practices. However, they may not be. As new developments in the field of relationship testing occur, changes may be recommended to the AABB Standards for Blood Banks and Transfusion Services. It is not possible, however, to revise each publication at the time such a change is adopted. Thus, it is essential that the most recent edition of the Standards be consulted as a reference in regard to current acceptable practices.
Copyright © 2018 by AABB.  Permission to republish on PathLabTalk has been granted by AABB.
If you would like to purchase the source material this was quoted from, please visit here.
Submitter Cliff Category BloodBankTalk Submitted 05/02/2022  

I just answered this question.

My Score PASS  

I just answered this question.

My Score FAIL  

I just answered this question.

My Score PASS  

I just answered this question.

My Score FAIL  

I just answered this question.

My Score PASS  

I believe the product code doesn't need to change if it's directed donation. But of course if it was autologous, it needs to be changed. 
https://www.iccbba.org/isbt-128-basics/frequently-asked-questions/national

I have encountered a case, there was a 10 month baby boy, he was A type, but there was anti-A in his serum and on his red cells we also eluated anti-A.
His mom was A type with auto anti-A.
1.I remember the books say maternal origin antibodies will disappear 6 monthes after birth, maybe the books are lying😃 or there are some other reasons. He was breast feeded.
2.His mom looks healthy even with auto anti-A, but the baby developed hemolysis, why?
Thanks in advance for your help.
 

We have a handout we created (fact sheet) and one the state of CA says that the MD gives to patient's, family, etc. prior to obtaining consent to transfuse.  This might be what you are looking for.
TRANSFUSION FACT SHEET ENGLISH 07 2018-no track changes.doc Blood Transfusion Brochure (1)_CA_June 2018.pdf

First of all, please do not worry.  IF you do have anti-D antibodies, and they are real antibodies, this is only one of a number of tests that the doctors will do during your pregnancy to make sure everything is going OK with your baby.  
What they should do is recheck your blood for anti-D levels now and again in about 4 weeks' time to see if there is any change.  It will show anti-D because of the Rhogam, but the important thing is to see whether the level increases significantly over time.  Also, even now, if it is very high (VERY unlikely) then that would indicate it's real anti-D as opposed to the Rhogam.
Ultrasound is a good idea.  It is usually done anyway during pregnancy, but it will also show if something is happening that they need to react to.

Weekly ultrasounds and nst thru biweekly appts. Most recent ultrasound showed no signs of hydrops or any other issues thankfully, aside from 1.7 MoM, next day another ultrasound MoM dropped to 1.3. Could need IUT Between now (32 weeks) and 34 weeks depending on how these numbers change, after that will just induce if needed, will be induced before 37 weeks for sure at Mfm hospital with nicu. Re-ran titer - 1:256 (said they don’t dilute further beyond this). Given it was negative at 13 weeks, they have no idea how it happened given it was previously negative and no reason for it to have ever been positive. MFM said I’m only the second he’s ever had to have this in a first pregnancy. Doc said lab that ran the original bloodwork has changed their procedures bc of this case, so that is good! 

If you subscribe to a whole Blood Proficiency test ( like CAP JAT) the samples contain reverse group antibodies anti A, Anti B etc. and a couple of antibodies. its easy to write your own study looking for carryover in the adjacent samples.  Alternatively Hemo bioscience makes and sells a validation kit for instrumentation and this contains similar materials....

Attached is my procedures for creating labels (we only use it for computer downtime) using Digi-Trax's HemaTrax Unity Client (111119 version) and the older version we used to have.  We used to have to hand create our labels prior to moving from a very old version of Meditech to Mediware (now WellSky) in 2013, so I attached our Preparation of Aliquots from 2008 because page 10 has our log for creating aliquots, pooling and sterile docking use and page 11 has the expiration date/time grid (24 hour clock).  Hopefully some or all of this helps.  
BBI0014 Labeling Blood Products_111119.doc BBI0014 Labeling Blood Products.doc BBC015.6 Preparation of Aliquots.doc

We only use Hematrax just in the event that our LIS is down and unavailable. You have no LIS for your lab? So your lab results are handwritten? I can give you instructions on how to use it but I would need time to dig them up. I will if you still need help. Good luck. 

I would love step-by-step instructions on changing the expiration dates in Hematrax. We currently do not have a lab LIS, and I would hate to fumble around and screw this up. Any help will be appreciated.

FDA approval came through last year.

We regularly used to run RT or even cold gel panels (LISS cells on Saline cards) to id M, P1, Le etc.
If suspected A2 patient with anti-A1, use A2 cells in the reverse grouping card.
We would test the grouping cells for the identified antibody.
WARNING! These may require a degree of skill as may have to perform manual testing.